Back to top
more

Bolt Biotherapeutics (BOLT)

(Delayed Data from NSDQ)

$1.16 USD

1.16
13,256

-0.04 (-3.35%)

Updated Apr 25, 2024 03:58 PM ET

After-Market: $1.15 -0.01 (-0.86%) 4:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BOLT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Bolt Biotherapeutics, Inc. [BOLT]

Reports for Purchase

Showing records 1 - 16 ( 16 total )

Company: Bolt Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/22/2024

Company Report

Pages: 8

4Q23 Results; Trastuzumab Imbotolimod (BDC-1001) Phase 2 Data and First BDC-3042 Data Anticipated in 2024

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Bolt Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

12/05/2023

Daily Note

Pages: 3

First Patient Dosed in Phase 2 Trial of BDC-1001 in Patients With HER2-Positive Breast Cancer Following Enhertu

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Bolt Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

11/10/2023

Company Report

Pages: 8

3Q23 Results; Initial Phase 2 BDC-1001 Data Expected Next Year

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Bolt Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

10/24/2023

Company Report

Pages: 8

Positive Update For BDC-1001 Presented at ESMO 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Bolt Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

10/17/2023

Daily Note

Pages: 3

First Patient Dosed in Phase 1/2 Study of BDC-3042

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Bolt Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

09/28/2023

Daily Note

Pages: 3

FDA Grants Orphan Drug Designation to BDC-1001 For the Treatment of Gastric Cancers

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Bolt Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

08/08/2023

Company Report

Pages: 8

2Q23 Results; First Patients Dosed in Phase 2 Study of BDC-1001

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Bolt Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

08/03/2023

Daily Note

Pages: 3

First Patients Dosed in Phase 2 Dose-Expansion Trial of BDC-1001 in HER2-Positive Tumors

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Bolt Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

06/05/2023

Company Report

Pages: 8

BDC-1001 Phase 1 Data in 131 Patients Presented at ASCO; Phase 2 Studies Underway in Four Tumor Types

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Bolt Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

05/26/2023

Company Report

Pages: 8

Monotherapy and Combination Data Presented in ASCO Abstract For BDC-1001

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Bolt Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

05/12/2023

Company Report

Pages: 8

1Q23 Results; Full Phase 1 BDC-1001 Data at ASCO; BDC-3042 Could Enter the Clinic This Fall

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Bolt Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

03/30/2023

Company Report

Pages: 8

4Q22 Results; Positive Top-Line Phase 1 Dose Escalation Results For BDC-1001 Announced

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Bolt Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

11/11/2022

Company Report

Pages: 5

3Q22 Results; BDC-1001 Phase 1/2 Topline Data and RP2D Expected 1Q23

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Bolt Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

10/04/2022

Company Report

Pages: 29

This Immuno-Oncology Company Could Spark Investor Interest; Initiate With Buy Rating and $8 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 35.00

Research Provided by a Third Party

Company: Bolt Biotherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for BOLT

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Bolt Biotherapeutics, Inc.

Industry: Oil and Gas - Mechanical and and Equipment

Record: 16

01/27/2010

Company Report

Pages: 5

Dropping coverage due to weaker than expected performance.

Provider: SINGULAR RESEARCH

Analyst: GARNER G

Price: 10.00

Research Provided by a Third Party